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4ABBREVIATIONS
Ang Angiopoietin
BEC blood vascular endothelial cell
BM basement membrane
DNA deoxyribonucleic acid
E embryonic day
EC endothelial cell
ECM extracellular matrix
EGF epidermal growth factor
FGF fibroblast growth factor
Flk1 fetal liver kinase 1 (VEGFR-2)
Flt1 fms-like tyrosine kinase 1 (VEGFR-1)
Flt4 fms-like tyrosine kinase 4 (VEGFR-3)
GAP GTPase-activating protein
GTP guanosine triphosphate
Ig Immunoglobulin
KDR kinase insert domain containing receptor (VEGFR-2)
LEC lymphatic endothelial cell
MAPK  mitogen activated protein kinase
NRP neuropilin
PDGF platelet-derived growth factor
PECAM platelet-endothelial cell adhesion molecule
PI3-K phosphatidylinositol 3-kinase
PKC protein kinase C
PLCγ phospholipase C-gamma
PlGF placenta growth factor
Prox-1 prospero-related homeobox protein 1
RNA ribonucleic acid
RTK receptor tyrosine kinase
SMC smooth muscle cell
Tek Tunica interna endothelial cell kinase (Tie-2)
TGF transforming growth factor
Tie Tyrosine kinase with immunoglobulin and EGF homolygy domains
TNF tumor necrosis factor
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
VPF vascular permebility factor (VEGF)
VRF VEGF related factor (VEGF-B)
VRP VEGF related protein (VEGF-C)
vWF von Willebrand Factor
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6ABSTRACT
Blood and lymphatic vessels form a
circulatory system, which allows the
transportation of metabolic substances, cells
and proteins in the body. A major role of the
lymphatic vasculature is to return an excess
of the protein-rich interstitial fluid to the
blood circulation. Until recently, studies of
the lymphatic vessels were hampered due to
the lack of specific markers, but to date
several such markers have been identified. In
addition, recent studies have indicated an
important role for lymphatic vessels in
certain developmental disorders, such as
lymphedema, and as a route for metastasis of
tumors. These findings have brought
lymphatic biology to the forefront of vascular
research.
Two members of the VEGF (vascular
endothelial growth factor) family of growth
factors, VEGF-C and VEGF-D, have been
shown to stimulate the growth of lymphatic
vessels via lymphatic endothelial cell
receptor, VEGFR-3. Although VEGFR-3 is
required for the development of the blood
vascular system during early embryonic
development, later on its expression becomes
restricted to lymphatic endothelial cells and it
thus serves as a marker of these cells in adult
tissues. Recent studies also demonstrate that
VEGFR-3 and its ligands are involved in the
development of lymphedema and lymphatic
metastasis.
This study was undertaken to obtain
more information concerning the molecular
mechanisms regulating the development and
growth of lymphatic vessels, concentrating on
the role of VEGFR-3 in these processes. We
showed that VEGFR-3 mediates proliferation,
survival and migration of lymphatic
endothelial cells and demonstrated that
VEGFR-3 function is required for the normal
development of lymphatic vasculature.
Blocking of VEGFR-3 signaling inhibited
specifically lymphangiogenesis without
affecting blood vessels, indicating that distinct
molecular mechanisms control the
development of the two vascular systems. We
also analysed the genetic programs which
determine the lymphatic and blood vascular
endothelial cell identities, and identified the
homeobox transcription factor Prox-1 as a fate
determining factor for lymphatic endothelial
cells. These studies give new insights into the
phenotypic diversity of endothelial cells and
reveal new potential vascular markers, some
of which could provide important targets for
the treatment of diseases characterised by
abnormal angiogenesis or lymphangiogenesis.
7REVIEW OF THE LITERATURE
1. Cell signaling by receptor tyrosine kinases
Coordinated growth and differentiation of
cells and their organisation into specific
tissues depend on cell-cell signaling. Some of
these signals are mediated via secreted
growth factors which bind to their receptors
on the surface of target cells. The receptor-
mediated activation of intracellular signaling
cascades usually target transcription factors,
modify their activity and reprogram gene
expression. Covalent modification of proteins
by reversible phosphorylation accomplished
by protein kinases is a key mechanism by
which intracellular signals are transduced
from the cell surface to the nucleus. Growth
factor receptors having an intrinsic protein
tyrosine kinase activities have been
characterised as pehaps the most important
regulators of cellular functions. In addition to
receptor tyrosine kinases (RTK), other
membrane receptors including integrins and
guanosine triphosphate-binding protein (G
protein)-coupled receptors transduce
extracellular signals into the cell and regulate
important cellular processes such as cell
migration and survival (Lowes et al., 2002;
Schwartz, 2001). To increase complexity,
many intracellular signaling molecules
participate in several signaling cascades.
Cell-type specific expression of receptors and
effector proteins and the availability of
cognate ligands as well as the strength and
persistence of the signal all affect how the
cell responds to the stimulus. In addition,
cellular history defines the developmental
competence of the cell and its ability to
respond to growth factor stimuli.
1.1. RTK activation
RTKs are divided into distinct subclasses
based on their structural characteristics and
sequence similarities in their catalytic domain
(van der Geer et al., 1994). All RTKs have a
ligand-binding extracellular domain, a single
hydrophobic transmembrane region and a
cytoplasmic portion containing the kinase
domain that catalyses the transfer of γ-
phosphate from ATP to the acceptor tyrosine
residues of target proteins.
RTKs dimerise in response to binding
of specific ligands. Presumably the close
contacts between receptor monomers lead to
phosphorylation of tyrosine residue(s) in the
activation loop in the catalytic domain. The
phosphorylation induces a conformational
change which permits ATP binding into the
kinase active site and allows the
transphosphorylation to proceed, leading to
stimulation of the kinase activity (Hubbard,
1997; Lemmon and Schlessinger, 1994). The
phosphorylation of tyrosine residues outside
the catalytic domain then creates docking
sites for intracellular signaling molecules
containing Src homology 2 (SH2) and
phosphotyrosine-binding (PTB) domains and
leads to assembly of intracellular signaling
complexes (Schlessinger, 2000).
The most common RTK ligands are
secreted growth factors. After being released
from the producer cells they usually diffuse
relatively short distances in the extracellular
matrix until they encounter their target cells.
On the other hand, some growth factors bind
to the pericellular matrix or are anchored to
the cell surface and require close cell-cell
contacts in order to bind and activate their
receptors on the neighbouring cells. Many of
the ligands act as dimers which can form
stable receptor dimers by simultaneously
binding two receptors. However, certain
monomeric bivalent ligands, such as
epidermal growth factor (EGF), have one
8strong and one weak receptor binding site and
may induce receptor activation in a different
manner. Even without ligand, EGF receptors
have an ability to form dimers, and exist as
preformed dimers on the cell surface (Moriki
et al., 2001). Rather than causing receptor
dimerisation ligand binding induces a rotation
of the juxtamembrane and transmembrane
regions, which causes the dissociation of the
intracellular domains. The catalytic kinase
domains then become accessible to their
substrate tyrosine residues (Moriki et al.,
2001). The activation of preformed receptor
dimers via induction of conformational
changes rather than through induction of
receptor dimerisation may be a more
commonly used mechanism in RTK signaling
than first believed (Livnah et al., 1999).
Another monomeric ligand, fibroblast growth
factor (FGF) binds it’s receptors
monovalently and therefore it requires the
assistance of accessory molecules, heparan
sulphate proteoglycans, in order to activate
the dimerisation and transphosphorylation of
the receptors (Schlessinger et al., 2000;
Spivak-Kroizman et al., 1994).
1.2. Signal transduction
RTK-induced activation of intracellular
signaling molecules is usually accomplished
by phosphorylation-induced membrane
translocation or conformational changes.
Although many signaling cascades ultimately
target transcription factors and thus regulate
gene expression, cells respond to RTK
signaling also by changing their metabolism
and cytoskeletal arrangements.
A large family of intracellular
signaling molecules possess intrinsic
enzymatic activities such as protein kinase,
phosphatase, phospholipase activities or
GTPase-activating nucleotide exchange
activity (Schlessinger, 2000).  Other
molecules are adaptor proteins which provide
links between different signaling molecules
and networks. A classical example of the
signal transduction patways activated via
growth factor signaling is the Ras/MAP
(mitogen activated protein) kinase cascade.
Ras is a GTPase whose importance in cell
proliferation and differentiation is well
recognised through many oncogenic forms of
Ras that have been found in cancers. Once
activated via a guanine nucleotide exchange
factor, Sos, the GTP-bound Ras recruits a
serine kinase Raf to the plasma membrane.
The interaction with Ras is necessary for Raf
activation, but possibly an additional event
such as phosphorylation is also required.
After membrane translocation Raf can be
phosphorylated for example by members of
the membrane-associated Src family kinases.
Activated Raf then starts a kinase cascade
including MAPK kinase and MAP kinase
(Fig. 1). MAP kinases are a family of
enzymes some of which can translocate into
the nucleus and phosphorylate and activate
transcription factors. In addition to inducing
cell proliferation, the highly conserved
MAPK cascades regulate metabolic
processes, cell survival, differentiation, cell
cycle and cell migration in all eukaryotes
(Chang and Karin, 2001)
S e v e r a l  R T K s  s t i m u l a t e
phosphoinositol metabolism. RTK-activated
phospholipase C-γ catalyses the hydrolysis of
phosphatidylinositol (4,5)-bisphosphate
(PIP2) to generate second messengers
diacylglycerol and inositol-1,4,5 triphosphate
(IP3), which then regulates intracellular Ca
2+
levels (Fig. 1). The phospholipid kinase PI3-
kinase activates another signaling cascade.
The p85 adaptor subunit of PI3-kinase can
bind to the phosphorylated residues in
transmembrane receptors and recruit the
catalytic p110 unit into the complex at the
cell membrane. This activates the enzymatic
activity of p110 and leads to phosphorylation
of membrane-localized phosphoinositides
which in turn act as second messengers. PI3-
kinase products activate serine/threonine
9kinase Akt which can modify the activity of
pro- and anti-apoptotic proteins, transcription
factors and their  regulators by
phosphorylation. Direct Akt targets include
for example a pro-apoptotic protein BAD,
caspase 9, the NF-κB regulator IKK and
some members of the Forkhead family of
transcription factors, which are important
regulators of cell survival (Datta et al., 1999).
Figure 1. A schematic figure of the
receptor tyrosine kinase activated
intracellular signal transduction pathways.
Ligand binding to the extracellular domain
causes the dimerisation of receptor
monomers. Mutual transphosphorylation
between the catalytic domains (black
boxes) activates the kinase activity and
phosphorylation of tyrosine residues
outside the catalytic domain then creates
docking sites (P) for intracellular signaling
molecules. Activation of intracellular
signaling pathways including Ras, PLC-γ
and PI3-kinase cascades then lead to
cellular responses such as proliferation,
migration or survival.
1.3. Signal down-regulation
There are several mechanisms by which RTK
activity and tyrosine phosphorylation are
regulated inside the cell. Naturally occurring
RTK antagonists and soluble receptor
variants provide mechanisms for the
inhibition of receptor activation (Kendall and
Thomas, 1993; Maisonpierre et al., 1997).
RTKs may also contain domains with
repressor functions which keep them in an
inactive state (Gille et al., 2000; Tao et al.,
2001). For example, the juxtamembrane
region of vascular endothelial growth factor
receptor 1 (VEGFR-1) contains a represssor
sequence which inhibits receptor activity
(Gille et al., 2000).
Phosphorylation by serine/theronine
kinases may also regulate RTK activity,
enabling unrelated kinases to down-regulate
each other. For example, protein kinase C
(PKC) can phosphorylate EGF receptor on
multiple serine and threonine residues. PKC-
induced phosphorylation of EGFR decreases
its tyrosine kinase activity and therefore
results in the inhibition of EGF signaling
(Cochet et al., 1984; Schlessinger, 2000). By
competing for the binding of the same
receptor motif, intracellular inhibitor proteins
can block effector protein activation without
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modifying RTK activity (Emanuelli et al.,
2000). Furthermore, the level of tyrosine
phosphorylation is under tight regulation by
tyrosine phosphatases (Ostman and Bohmer,
2001). Finally, ligand-induced internalisation
of the receptor-ligand complexes usually
leads to lysosomal degradation of the
receptor.
Since RTKs regulate cellular
proliferation, their aberrant expression or
dysfunction may lead to uncontrolled growth.
For example, several transforming oncogenes
encode for constitutive active mutated forms
of RTKs or their down-stream effector
proteins. Activating or inactivating RTK
mutations can also lead to developmental
disorders.
2. Development of the vascular system
2.1. Vasculogenesis and angiogenesis
During embryogenesis the cardiovascular
system is the first functional organ system
and its development and growth are essential
for maintaining the growth of the whole
embryo. The endothelial cells lining the
blood vessels differentiate from mesodermal
precursor cells, angioblasts, to form a
primitive vascular network in a process called
vasculogenesis (Risau, 1997; Risau and
Flamme, 1995). The primitive plexus of
homogenously sized endothelial tubes is then
extensively remodeled into a more mature
vessel network consisting of a hierarchy of
larger and smaller blood vessels (Fig. 2). This
remodeling occurs both by regression of the
vessels and by angiogenesis, consisting of
sprouting, splitting or fusion of pre-existing
vessels to adjust the vascular density
according to the metabolic requirements of a
certain tissue or organ (Carmeliet, 2000;
Risau, 1997). Soon after the formation of the
vessels, endothelial cells become surrounded
by pericytes or vascular smooth muscle cells
(Fig. 2).
Pericytes and endothelial cells share a
common basement membrane (BM) which is
a thin sheet-like extracellular matrix between
the two cell types. The main structural
constituents of the BM include fibronectin,
laminin, collagens and heparan sulphate
proteoglycans. Depending on the type of the
vessel and on the tissue environment the
composition of the vascular BM is variable.
Failure to form a proper BM can lead to
decreased pericyte adhesion and migration
and to defects in vessel stability, indicating
an important role for the BM in normal
vascular development (Beltramo et al., 2002;
Thyboll et al., 2002).
Already before the onset of blood
circulation, the endothelial tubes are specified
as two parallel but distinct vascular networks,
arteries and veins. The normal sprouting and
branching of the maturing vasculature
involve repulsive signals which prevent
arteries and veins from fusing together.
Failure in the establishment of the arterial and
venous identity leads to vascular dysplasia
(Urness et al., 2000). Recent studies have
shed light on the molecular basis for this
identity. For example, interaction between
EphrinB2 in arteries and its receptor EphB4
in veins is important in defining the
boundaries between these vessels (Adams et
al., 1999; Wang et al., 1998). Furthermore,
signaling via Notch (Lawson et al., 2001;
Zhong et al., 2001) and activin receptor-like
kinase-1 (Urness et al., 2000) induce the
expression of arterial genes and supress
venous-specific genes. Therefore these
molecules have a crucial role in the proper
arterial-venous differentiation.
While vasculogenesis is mainly
thought to be restricted to embryonic
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development, angiogenesis has an important
role throughout adult life in physiological
processes such as in the female reproductive
cycle and in wound healing. Although the
endothelial cells remain quiescent for most of
their life in adult organisms, upon angiogenic
stimuli they can enter the cell cycle and
proliferate rapidly. Endothelial cells are also
activated to secrete proteolytic enzymes
which degrade the basement membrane, to
migrate towards the stimuli and to form
capillary sprouts. However, during normal
p h y s i o l o g i c a l  a n g i o g e n e s i s  t h e
neovascularisation is short-lived and
discontinuation of the stimulus leads to
involution and disappearance of the newly
formed vessels, as in the case of the
granulation tissue of a healing wound. In
contrast, in certain pathological conditions,
such as in cancer and in chronic
i n f l a m m a t o r y  d i s o r d e r s ,  t h e
neovascularisation is sustained and excessive
angiogenesis contributes to the development
of these diseases (Carmeliet and Jain, 2000;
Folkman, 1995; Folkman, 1996). Knowledge
of the molecular mechanisms by which
angiogenesis is controlled may yield
strategies for the treatment of diseases
characterised by abnormal angiogenesis, and
understandably the field has received a lot of
research interest during the past decades.
Figure 2. Development of the embryonic blood and lymphatic vessels. During vasculogenesis the
endothelial precursor cells, angioblasts, form a primitive capillary plexus which is then further remodelled
via angiogenesis. Vessel stabilisation requires the recruitment of smooth muscle cells (SMC). Lymphatic
vessels arise by sprouting from the veins. Adapted from (Alitalo and Carmeliet, 2002; Conway et al., 2001).
2.2. Lymphangiogenesis
Due to high pressure inside the blood vessels
fluid continuously escapes from the blood
capillaries to the surrounding tissue. A major
function of the lymphatic system is to
transport this extravasated fluid as well as
cells and plasma proteins back to the blood
circulation. In addition, the lymphatic
vasculature is an important part of the
immune system, since it filters lymph and its
antigens through lymph nodes. Lymphatic
vessels also serve as one of the major routes
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for absorption of lipids from the gut (Witte et
al., 2001).
Lymphatic vessels are characterised
by irregular lumen with no red blood cells
inside, they have discontinuous basal lamina,
overlapping intercellular junctional
complexes and anchoring filaments that
connect endothelial cells to the extracellular
matrix and hold the vessels open when the
pressure rises in the interstitial tissue (Witte
et al., 1997). Lymphatic vessels possess an
intrinsic contractility and larger vessels have
smooth muscle cell coverage which helps to
pump the lymph fluid forward. The lymph
flow is also sustained by arterial pulsation
and skeletal muscle movements while the
luminal valves prevent backflow (Witte et al.,
1997).
During development, the lymphatic
vessels arise after the establisment of the
blood circulatory system. In the early 20th
century, Florence Sabin described the growth
of lymphatic vessels by centrifugal sprouting
from the lymph sacs which are formed in the
vicinity of veins at specific areas in embryos
(Sabin, 1902; Sabin, 1909). More recently
gathered molecular biological data support
Sabin’s theory of the venous origin of
lymphatic vessels (Dumont et al., 1998;
Wigle et al., 2002; Wigle and Oliver, 1999).
A homeobox transcription factor Prox-1 has
an important role in the formation of the
lymph sacs by endothelial cell sprouting from
the veins. At the stage when lymphatic
development starts Prox-1 is expressed in a
subpopulation of endothelial cells which
migrate from the anterior cardinal vein and
give rise to lymphatic endothelial cells
(Wigle and Oliver, 1999; Fig.2). Targeted
inactivation of Prox-1 leads to the arrest of
this budding and, as a result the Prox-1-/-
embryos do not develop lymphatic vessels
whereas blood vessel development is not
affected (Wigle and Oliver, 1999).
Another theory postulates that the
lymphatic endothelial cells are derived from
mesenchymal precursor cells (Huntington
and McClure, 1908; Kampmeier, 1912). The
recent finding of these precursors,
lymphangioblasts, in the embryonic
mesenchyme of avians supports this theory
(Papoutsi et al., 2001; Schneider et al., 1999).
Therefore, at least during embryogenesis both
sprouting lymphagiogenesis and the
differentiation of mesenchymal cells into
lymphatic endothelial cells may contribute to
the formation of lymphatic vessels.
2.3. Phylogeny of blood and lymphatic
vessels
The complexity of the vascular system
increases in the phylogeny of animals.
Besides being an interesting subject from an
evolutionary point of view, knowledge of the
differences and similarities between the
vascular systems in different animal species
may give insights into the mechanisms of
embryonic vascular development in
mammals.
When the size of organisms increased
during evolution, diffusion was no longer
sufficient and a blood circulatory system
evolved to provide transportation of nutrients,
oxygen and waste products. In invertebrates,
the endothelial cells are often widely
separated from each other and the
permeability of vessels is limited by the
pericyte layer surrounding the endothelium
while the reverse occurs in vertebrates
(Casley-Smith, 1987). Also, in the more
primitive chordates the endothelial cells of
the smallest vessels are separated by gaps and
only the larger and the central vessels have
continuous endothelium as in mammals.
Fenestated endothelium, which allows local
exhange of fluid and macromolecules,
appears first in hagfish (Casley-Smith, 1987).
More commonly the fenestrated endothelium
occurs in elasmobrances, where it is
responsible for the uptake of lipoproteins in
the gut and therefore it carries out some
13
functions similar to those of the mammalian
lymphatic endothelium.
When animals became even larger
and more active, increased blood pressure
was required to push blood throughout the
body. To prevent rupture of the vessels by the
high pressure, capillaries became surrounded
by a basement membrane and larger blood
vessels by elastic tissue and muscle. In
parallel with increased blood pressure more
protein and fluid leaked out to the tissues and
there was a need for the lymphatic
vasculature to develop. Teleost fish have two
circulatory systems, primary and secondary
circulation. The primary and secondary
arteries of these fish are directly connected
via interarterial anastomoses, which prevent
the entry of red blood cells into the secondary
circulation but allow the white blood cells
and plasma proteins to enter (Steffensen and
Lomholt, 1992). While it is not generally
accepted whether the secondary circulation of
teleost fish can be considered a real
lymphatic vasculature, well-developed
lymphatic vessels are detected in amphibians
(Kotani, 1990; Vogel, 1985). In tailless
amphibians, such as frogs, the lymphatic
vessels however perform specialised
function. The large subcutaneous lymph sacs
are involved in maintaining body temperature
and act as a water store in certain species.
Both in amphibians and reptiles, the aorta
runs inside a lymph sinus equivalent to the
mammalian thoracic duct (Kotani, 1990). In
higher vertebrates, such as birds and
mammals, the lymphatic vessels may
envelope and run parallel to the blood
vessels, but never enclose them.
Interestingly, small venous vessels of
the elasmobranchs have openable inter-
endothelial structures, a discontinuous
basement membrane and connective tissue
fibrils attached to the endothelial cells; in
other words they resemble lymphatic vessels
of higher vertebrates. The functions of the
lymphatic vessels is presumably performed in
these animals by the openable endothelial
intercellular junctions of venous capillaries
which are opened by swimming activity
(Casley-Smith, 1987). Therefore, similarly to
mammalian embryonic development, the
veins may have preceeded lymphatic vessels
also in evolution.
2.4. Molecular identity of lymphatic versus
blood vascular endothelial cells
In addition to neovascularisation, the
endothelium has a variety of other important
functions e.g. in regulating the vascular tone,
maintaining the blood-brain barrier and in
inflammatory responses. For example,
endothelial cells recruit leukocytes to the
inflammatory foci and specialized endothelial
cells are responsible for the homing of
lymphocytes to the secondary lymphoid
organs (Biedermann, 2001). Reflecting the
functional diversity, the antigenic profile of
the vascular endothelium varies in different
types of vessels and in different organs.
In clinical studies pan-endothelial cell
markers serve as important tools for the
histochemical identification of vessels. For
example, the platelet-endothelial cell
adhesion molecule (PECAM-1/CD31) and
von Willebrand Factor are molecules which
are relatively commonly expressed in all
endothelial cells (Sleeman et al., 2001; Table
I). In studies of a number of physiological as
well as pathological conditions it is also
important to discriminate between blood and
lymphatic vessels. Only quite recently,
lymphatic endothelial cell markers have been
identified. These lymphatic endothelium
specific molecules include VEGFR-3
receptor tyrosine kinase, the Prox-1
transcription factor and the membrane
mucoprotein podoplanin (Breiteneder-Geleff
et al., 1999; Jussila et al., 1998; Wigle and
Oliver, 1999; Table I). None of these
molecules is specific for endothelial cells and
on the other hand, they may be expressed
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only in a subset of the lymphatic vessels. In
addition, the function of many of these
molecules in lymphatic endothelial cell
biology remains to be characterised.
However, identification of the lymphatic
markers has enabled the detailed studies of
lymphatic vessels and provided important
information of the functional properties of
lymphatic endothelial cells and of the
coordinated development and growth of the
blood and lymphatic vasculatures.
Table I. Examples of endothelial cell markers
Antigen EC1 Function/molecular identity Reference
PECAM-1/CD31 P adhesion molecule
CD34 B,(L) adhesion molecule
von Willebrand Factor B,(L) platelet adhesion
PAL-E B antigen unknown (Schlingemann et al.,
1985)
VEGFR-3 L receptor tyrosine kinase (Jussila et al., 1998)
LYVE-1 L lymphatic hyaluronan receptor (Banerji et al., 1999)
Prox-1 L homeobox transcription factor (Wigle and Oliver, 1999)
Desmoplakin I and II L intercellular adherens junction molecule (Ebata et al., 2001)
Podoplanin L integral membrane protein (Breiteneder-Geleff et al.,
1999)
D6 L β-chemokine receptor (Nibbs et al., 2001)
Macrophage mannose
receptor I
L endocytotic/phagocytotic receptor in
macrophages
(Irjala et al., 2001)
1 Endothelial cell (EC) expression; P=panendothelial, B=blood vessel endothelial, L=lymphatic endothelial
3. Molecular regulation of vascular development
3.1. Angiogenic and lymphangiogenic
factors
Angiogenesis is a multistep process
controlled by an interplay between
stimulators and inhibitors. Many angiogenic
factors have been identified by a variety of in
vivo systems, including chorioallantoic
membrane and rabbit corneal assays, and
subsequently their effects on the different
steps of angiogenesis have been dissected
using in vitro systems. Angiogenic factors
can act directly by stimulating endothelial
cells and/or indirectly by stimulating
accessory cells such as macrophages and
stromal cells. For example, transforming
growth factor-ß (TGF-ß) and EGF mediate
angiogenic effects indirectly by stimulating
other cells to produce angiogenic factors
(Goldman et al., 1993; Pertovaara et al. ,
1994). Due to the indirect action, candidate
angiogenic factors may have opposite actions
in vitro to that expected from in vivo
experiments and vice versa. For example,
TGF-ß inhibits endothelial cell growth in
vitro but stimulates angiogenesis in vivo.
Many of the important polypeptides involved
in vascular development have mitogenic and
chemotactic activity towards several cell
types. These factors include for example
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platelet-derived growth factor (PDGF) and
one of the most potent angiogenic factor,
FGF. However, some factors, such as VEGF
and Angiopoietins target endothelial cells
since their receptors are expressed relatively
specifically on these cells.
3.1.1. VEGF family of growth factors
VEGFs form a family of secreted
glycoproteins which have the characteristic
cystine knot growth factor domain common
in the PDGF/VEGF superfamily. VEGFs are
disulphide-linked or non-covalent dimers in
an antiparallel orientation. Presently, five
known members of the VEGF-family have
been identified: VEGF, placenta growth
factor (PlGF), VEGF-B, VEGF-C and
VEGF-D (reviewed in Veikkola et al., 2000).
All VEGFs have unique but overlapping
patterns of expression and binding to the
VEGF receptor tyrosine kinases and
neuropilin co-receptors (Fig. 3).
VEGF is one of the most important
regulators of both physiological and
pathological angiogenesis. It was first
isolated from tumor cells due to its ability to
induce vascular permeability (Senger et al.,
1983). Subsequently, VEGF has been shown
to stimulate endothelial cell proliferation,
migration and survival (reviewed in (Ferrara,
1999). VEGF is indispensable for embryonic
development, since inactivation of even one
VEGF allele results in embryonic lethality at
E11-12 in mice due to failure to establish a
normal blood vascular system (Carmeliet et
al., 1996; Ferrara et al., 1996). Even during
postnatal growth and development, VEGF
continues to be critical and its withdrawal
results in endothelial cell apoptosis and
inhibition of angiogenesis leading to blood
vessel regression (Aiello et al., 1995; Ferrara
et al., 1998; Gerber et al., 1999a). However,
after blood vessel maturation via the
recruitment of pericytes endothelial cells are
no longer dependent on VEGF for their
survival (Benjamin et al., 1998). VEGF is
expressed as several different splice-
isoforms, which appear to have unique
biological properties and tissue-specific
expression patterns (Carmeliet et al., 1999b;
Robinson and Stringer, 2001). The activity of
VEGF is mediated via two high-affinity
receptor tyrosine kinases, VEGFR-1 and
VEGFR-2, which are expressed primarily on
endothelial cells. However, six splice-
isoforms of VEGF display differential
binding to various coreceptors including
heparan sulphate proteoglycans and
neuropilin-1 and –2, which modulate their
biological activities (Gluzman-Poltorak et al.,
2000; Keyt et al., 1996; Soker et al., 1998).
Placenta growth factor (PlGF) and
VEGF-B (or VEGF-related factor, VRF) are
both expressed as two splice-isoforms
(Hauser and Weich, 1993; Maglione et al.,
1993; Olofsson et al., 1996b). Both PlGF and
VEGF-B bind to VEGFR-1 (Olofsson et al.,
1998; Terman et al., 1994) and NRP-1
(Makinen et al., 1999; Migdal et al., 1998),
and they can form heterodimers with VEGF
(DiSalvo et al., 1995; Olofsson et al., 1996a).
The biological functions of PlGF and VEGF-
B have remained largely unknown and there
is some controversy regarding whether they
are angiogenic or not. Both have been
reported to stimulate mitogenicity of
endothelial cells (Landgren et al., 1998;
Maglione et al., 1991; Olofsson et al., 1996a;
Sawano et al., 1996). Furthermore, in some
studies PlGF was shown to be angiogenic in
vivo (Ziche et al., 1997), while in others no
such effects were detected (Cao et al., 1996;
Oh et al., 1997). Several laboratories have
also found that PlGF induces migration of
VEGFR-1 expressing cells, including
monocytes and endothelial cells (Clauss et
al., 1996; Migdal et al., 1998; Ziche et al.,
1997). PlGF and VEGF-B are not required
for the normal vascular development of
mouse embryos (Aase et al., 2001; Carmeliet
et al., 2001). However, the absence of PlGF
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reduced angiogenesis and collateral growth in
pathological conditions (Carmeliet et al. ,
2001). Furthermore, VEGF-B deficient mice
may have impaired recovery from cardiac
ischemia (Bellomo et al., 2000). These results
suggest that both factors may have an
important role in regulating angiogenesis in
pathological situations.
Figure 3. VEGF family of growth factors and their binding to VEGF receptor tyrosine kinases (VEGFRs)
and Neuropilins (NRPs). Circle = immunoglobulin homology domain; black box=tyrosine kinase domain;
S-S= disulphide bond; oval=CUB (complement binding) domain; gray box=coagulation factor V/VIII
homology domain; hexagon= MAM (meprin, A5) domain.
VEGF-C (or VEGF-related protein,
VRP) and VEGF-D (or c-fos-induced growth
factor, FIGF) are expressed as prepro-
proteins which are proteolytically processed
into polypeptides with increasing affinity
towards VEGFR-3, and only their fully
processed forms can bind to and activate
VEGFR-2 (Joukov et al., 1997; Stacker et al.,
1999). However, although human VEGF-D is
a ligand for both VEGFR-2 and VEGFR-3,
mouse VEGF-D binds selectively to VEGFR-
3 (Baldwin et al., 2001). During embryonic
development VEGF-C is expressed in the
mesenchyme surrounding the developing
lymphatic vessels, which suggested its
possible role in the regulation of
lymphangiogenesis (Kukk et al., 1996).
Subsequently, both VEGF-C and VEGF-D
were shown to induce lymphatic growth in
vivo (Jeltsch et al., 1997; Oh et al., 1997;
Veikkola et al., 2001) and induce
proliferation and migration of lymphatic
endothelial cells in vitro (Marconcini et al.,
1999; Mäkinen et al., 2001b). At higher
concentrations and under specific conditions,
these factors can also stimulate the
proliferation and migration of blood vascular
endothelial cells, increase vascular
permeability and angiogenesis (Joukov et al.,
1997; Mäkinen et al., 2001b; Oh et al., 1997;
Witzenbichler et al., 1998). The VEGF-C/D
induced effects on blood vessel endothelium
are presumably mediated via VEGFR-2
activation, suggesting an important role for
specific proteolytic enzymes in regulating the
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lymphangiogenic versus angiogenic potential
of VEGF-C and VEGF-D.
Additional VEGF-like molecules have
been isolated from Orf-virus (Lyttle et al.,
1994) and from snake venom (Gasmi et al.,
2000; Komori et al., 1999). The double-
stranded poxvirus Orf infects sheep and goats
and induces proliferation of vascular
endothelial cells and dilation of blood vessels
(Lyttle et al., 1994). The VEGF-like
polypeptides encoded by the genomes of
three viral strains, NZ2, NZ7 and D1701,
were commonly named as VEGF-E, and
these polypeptides were found to induce
angiogenesis and microvessel permeability
by activating mammalian VEGFR-2 (Meyer
et al., 1999; Ogawa et al., 1998; Wise et al.,
1999). Most probably the VEGF-like
sequences found in the genomes of these
viruses was acquired from the host and the
gene product is responsible for the
angiogenic stimulus associated with the
infection.
3.1.2. Angiopoietin family
Angiopoietins form another family of growth
factors which specifically target endothelial
cells. Angiopoietin-1 (Ang-1) and Ang-2 are
ligands for the endothelial cell receptor
tyrosine kinase Tie-2/Tek (Davis et al., 1997;
Maisonpierre et al., 1997). In addition, mouse
Ang-3 and human Ang-4, which represent
interspecies orthologues, bind to Tie-2
(Valenzuela et al., 1999). Interestingly, these
ligands have opposing actions in Tie-2
function; Ang-1 and Ang-4 function as
activating ligands for Tie-2 while Ang-2 and
Ang-3 act as competitive antagonists. The
data from several mouse models with altered
Tie-2 signaling suggest that Tie-2 stimulation
by Ang-1 is required for the stabilisation of
the vessels and for the maintenance of the
interactions between the endothelium and
surrounding extracellular matrix and
mesenchyme (Sato et al., 1995; Suri et al.,
1997; Suri et al., 1998). In contrast, inhibition
of Tie-2 signaling by Ang-2 destabilises the
vessels by loosening the endothelial cell-
matrix contacts and making the cells
accessible and more responsive towards
angiogenic stimuli (Maisonpierre et al. ,
1997). Consistent with these observations,
Ang-2 expression in adult organisms is found
in tissues which undergo angiogenesis; e.g. in
placenta and in tumors (Etoh et al., 2001;
Goldman-Wohl et al., 2000; Koga et al. ,
2001).
Recent studies indicate a significant
interplay between Angiopoietins and VEGFs
in the formation of both blood and lymphatic
vessels. Low VEGF levels combined with
high expression of Ang-2 lead to vascular
regression, while Ang-1 and VEGF may
cooperate in promoting angiogenesis.
Interestingly, Ang-1 protects the vasculature
against VEGF-induced plasma leakage
(Thurston et al., 2000; Thurston et al., 1999).
On the other hand, Ang-2 may be involved in
the regulation of lymphangiogenesis, since
inactivation of Ang-2 leads to non-functional
and disconnected lymphatic vessels in mice
(G. Thurston, pers. comm.). In addition, both
VEGF and VEGF-C increase Ang-2 mRNA
in endothelial cells (Mandriota and Pepper,
1998; Oh et al., 1999; Veikkola et al. ,
unpublished observations).
3.2. Endothelial cell receptors
3.2.1. VEGF receptors
The three members of the family of VEGF
receptor tyrosine kinases (VEGFR-1-3) are
key regulators of the development and
maintenance of the vertebrate vascular
system. All VEGFRs have an extracellular
ligand-binding domain consisting of seven
immunoglobulin homology domains and an
intracellular kinase domain split by a kinase
insert (See Fig. 3).
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VEGFR-1 (or Flt-1) functions as a
receptor for VEGF, PlGF and VEGF-B. In
addition to the full-length receptor,
alternative splicing of the VEGFR-1 mRNA
generates a soluble form of the receptor,
which may antagonise VEGF function
(Kendall and Thomas, 1993). During
embryogenesis, targeted inactivation of
VEGFR-1 results in disorganization of blood
vessels due to increased production of
endothelial cells and death of mouse embryos
in utero at E8.5 (Fong et al., 1999; Fong et
al., 1995). In contrast, mice expressing
VEGFR-1 lacking the tyrosine kinase domain
survive and develop a normal vascular
system (Hiratsuka et al., 1998). These studies
suggest that during development VEGFR-1
may function only as a non-signaling
regulator of VEGF bioavailability (Shibuya,
2001). However, recent studies have provided
evidence that during adult life VEGFR-1
signaling may play an important role in
pathological angiogenesis and inflammation
(Carmeliet et al., 2001; P. Carmeliet, pers.
comm.). VEGFR-1 specific ligand PlGF can
stimulate angiogenesis and collateral growth
in ischemic heart and limb muscle.
Furthermore, inhibition of VEGFR-1
signaling impairs infiltration of VEGFR-1
expressing leucocytes in inflamed tissues and
suppresses mobilisation of bone-marrow
derived myeloid progenitor cells, resulting in
reduced bone and cartilage destruction in
arthritis (P. Carmeliet, pers. comm.).
Recruitment and migration of endothelial
progenitors and hematopoietic stem cells
from the bone marrow has been previously
shown to promote pathological angiogenesis
(Lyden et al., 2001).
VEGFR-1 has also been suggested to
regulate VEGFR-2 signaling by forming
heterodimers with it, although it seems to be
unclear whether VEGFR-1 acts by
antagonising VEGFR-2 functions (Rahimi et
al., 2000) or by mediating positive signals by
such heterodimers (Huang et al., 2001; P.
Carmeliet, pers. comm.).
VEGFR-2 (or KDR/Flk-1) is
considered to be the main signal transducing
VEGF receptor for angiogenesis and for
mitogenesis of endothelial cells. In addition
to VEGF, the proteolytically processed
mature forms of VEGF-C and VEGF-D bind
to and activate VEGFR-2 (Achen et al., 1998;
Joukov et al., 1997). Activation of VEGFR-2
stimulates endothelial cell proliferation,
migration and survival as well as blood vessel
permeability. Several intracellular signal
transduction pathways are activated via
VEGFR-2, including the MAPK and the PI3-
kinase pathways (reviewed in Matsumoto and
Claesson-Welsh, 2001; Petrova et al., 1999).
Mouse embryos deficient of VEGFR-2 die in
utero by E8.5-9.5 due to defective
development of both endothelial and
hematopoietic cells (Shalaby et al., 1995).
Although the hematopoietic/endothelial
progenitor cells are found in VEGFR-2
deficient embryos at E7.5, these cells fail to
migrate from the primitive streak to their
correct location in the yolk sac, where further
development into the hematopoietic and
endothelial cell lineages takes place (Shalaby
et al., 1997). In addition, VEGFR-2-/-
embryonic stem cells retain the potential to
form blood islands and to differentiate into
hematopoietic and endothelial cells in vitro
(Schuh et al., 1999; Shalaby et al., 1997).
Therefore it seems that the formation of
hematopoietic/endothelial cell precursors
occurs in the absense of VEGFR-2, but the
proper migration of these cells is dependent
on VEGFR-2-mediated signaling (Schuh et
al., 1999; Shalaby et al., 1997).
VEGFR-3 (or Flt4) is a receptor for
VEGF-C and VEGF-D (Achen et al., 1998;
Joukov et al., 1997). Human VEGFR-3 is
expressed as two isoforms generated by
differential splicing to the long terminal
repeat of an integrated endogenous retrovirus
between the last two exons (Hughes, 2001).
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The shorter transcript encodes a protein
lacking 65 amino acids in the C-terminus,
including three putative phosphorylated
tyrosine residues which may be important for
VEGFR-3 mediated signaling (Pajusola et al.,
1993). During early vascular development,
VEGFR-3 is expressed in developing blood
vessels and it is required for normal vascular
development. In the absense of VEGFR-3,
the embryos undergo normal vasculogenesis,
but the remodelling and maturation of
primary vascular networks is defective,
which leads to death in utero around E10 of
mouse development (Dumont et al., 1998).
However, after the formation of lymphatic
vessels VEGFR-3 is detected almost
exclusively on lymphatic endothelium
(Dumont et al., 1998; Kaipainen et al., 1995)
and it regulates the development and growth
of lymphatic vessels (Jeltsch et al., 1997;
Mäkinen et al., 2001a; Veikkola et al., 2001).
Besides lymphatic endothelia, in adult tissues
VEGFR-3 expression occurs also in
fenestrated endothelia (Partanen et al., 2000),
and in the endothelia of angiogenic blood
vessels in tumors (Partanen et al., 1999;
Valtola et al., 1999).
3.2.2. Tie receptors
Tie-1/Tie and Tie-2/Tek form another family
of endothelial cell specific receptor tyrosine
kinases. These receptors have a large
extracellular domain consisting of epidermal
growth factor homology domains,
immunoglobulin-homology domains and
fibronectin type III repeats. While several
Angiopoietin ligands have been identified for
Tie-2, Tie-1 is still an orphan receptor with
no known ligands.
Gene inactivation studies have
indicated that both Tie receptors have a
critical function in the formation of
embryonic blood vasculature. Mouse
embryos deficient of Tie-1 gene die between
E13.5–P0 due to failure in the establisment of
endothelial cell integrity which leads to
edema and haemorrages (Puri et al., 1995;
Sato et al., 1995). On the other hand, Tie-2
knock-out embryos die due to cardiovascular
defects and to defects in the expansion and
maintenance of the primitive capillary plexus
(Sato et al., 1995). The genetic studies
suggest that Tie-1 and Tie-2 are required for
the survival of endothelial cells starting from
late gestation throughout adult life (Jones et
al., 2001; Partanen et al., 1996; Puri et al.,
1999). Consistent with these findings, both
Tie-1 and Tie-2 can activate signal
transduction pathways which promote cell
survival (Hayes et al., 1999; Kontos et al.,
2002; Kontos et al., 1998; Papapetropoulos et
al., 2000).
Angiopoietin-Tie-2 signaling may
also have a role in the regulation of
endothelial cell-pericyte interactions.
Activating mutations of Tie-2 have been
detected in human patients having venous
malformations (Vikkula et al., 1996). These
lesions are characterised by enlarged blood
vessels with a lack of supporting smooth
muscle cells (Vikkula et al., 1996).
3.2.3. Neuropilins
Neuropilin-1 (NRP-1) and NRP-2 are
transmembrane non-tyrosine kinase receptors
expressed in the tips of growing axons (Chen
et al., 1997; Kawakami et al., 1996; Takagi et
al., 1995). NRP-1 interacts with receptors
belonging to the plexin family and these
receptor complexes mediate repulsive axon
guidance by binding semaphorins/collapsins
(Tamagnone et al., 1999). Both NRP-1 and
NRP-2 are, however, expressed also in
endothelial cells (Herzog et al., 2001;
Kitsukawa et al., 1995; Soker et al., 1998).
While NRP-1 is expressed mainly in arterial
endothelium (Moyon et al., 2001), NRP-2
appeares to be expressed in the endothelia of
embryonic veins and in adult tissues in some
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lymphatic vessels (Herzog et al., 2001;
Karkkainen et al., 2001).
Overexpression or inactivation of
NRP-1 in mouse embryos lead to lethal
abnormalities in both nervous and vascular
tissues (Kawasaki et al., 1999; Kitsukawa et
al., 1997; Kitsukawa et al., 1995). In contrast,
NRP-2 deficient mice are viable but they
have an abnormal organization and
fasciculation of several cranial and spinal
nerves (Chen et al., 2000; Giger et al., 2000).
Both NRP-1 and NRP-2 act as receptors for
several members of the VEGF family
(Neufeld et al., 2002; Fig. 3), suggesting that
the vascular defects in the NRP-1 mutant
mice may result from modulation of the
VEGF-induced angiogenesis by abnormal
NRP-1 levels. It seems that NRPs regulate
signal transduction by VEGFRs through
formation of receptor complexes (Fuh et al.,
2000; Gluzman-Poltorak et al., 2001;
Whitaker et al., 2001). It was also shown that
NRP-1 enhances the VEGF-induced
mitogenic signal of VEGFR-2 (Soker et al.,
1998) and that VEGFR-2 is not able to
efficiently transduce VEGF-mediated signals
in the absence of NRP-1 (Yamada et al.,
2001).
In neurons, NRP-1 ligand Sema3A
induces growth cone collapse and repulsion
of neurites, and during prolonged exposure, it
promotes apoptosis. Interestingly, in
neuroectodermal progenitor cells the
repulsive signals of Sema3A depended on the
expression of VEGFR-1 (Bagnard et al. ,
2001). Furthermore, Sema3A-induced
apoptosis of neuroectodermal progenitor cells
was antagonised by VEGF165 which
promoted cell survival, migration, and
proliferation (Bagnard et al., 2001). Similarly
in endothelial cells Sema3A acts as a
competitive inhibitor of VEGF-induced
motility and capillary sprouting (Miao et al.,
1999). These studies indicate that the balance
between Semaphorins and VEGFs can
modulate the migration, survival and
proliferation of neural progenitor cells as well
as endothelial cells through shared receptors.
NRPs may also induce biological responses
of VEGFs in cells which do not express
VEGFRs. For example, VEGF was shown to
induce tumor cell survival via NRP-1
interaction (Bachelder et al., 2001).
3.3. VEGFs and VEGFRs in the
development of other organ systems
Several studies have pointed out striking
similarities in the molecular mechanisms
which control the development of the
vascular and nervous systems. Several axon
guidance molecules have proved to be also
regulators of angiogenesis. These molecules
include for example Neuropilins and
Semaphorins. In addition, Eph receptors and
their ligands, Ephrins, are expressed both in
neural and endothelial cells and some of these
molecules are indispensable for the
development of both vascular and nervous
systems (Adams et al., 1999). These
observations raise questions whether the
angiogenesis regulators VEGFs and VEGFRs
might also have a role in the development of
the nervous system.
To date, little data is available on the
involvement of VEGFs and VEGFRs in
neural development. Both VEGFR-1 and
VEGFR-2 have been reported to occur in
neural cells, including retinal cells, Schwann
cells, dorsal root ganglia and astrocytes in the
central nervous system (Jin et al., 2000;
Krum and Rosenstein, 1998; Sondell et al.,
1999; Suzuma et al., 1998). In addition,
during embryonic development VEGFR-3 is
expressed in the notochord (Partanen et al.,
2000; Wilting et al., 1997). Furthermore,
VEGFR-3 deficient embryos appear to have a
neuronal phenotype which may be caused by
impaired survival of cells in the developing
neural tube (unpublished observations).
Recently, VEGF was reported to be a
survival factor for neuronal cells (Jin et al.,
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2000; Oosthuyse et al., 2001; Sondell et al.,
1999; Sondell et al., 2000) and VEGF-C may
possess a similar function (Olofsson et al.,
submitted). Although these functions were
suggested to be at least partly due to NRP-1
interactions, involvement of VEGFRs was
also proposed.
VEGF and its receptors are involved
also in the regulation of endochondral
ossification. Blocking of VEGF function
inhibits blood vessel invasion into the
hypertrophic zone of long bone growth plates
and results in impaired bone formation
(Gerber et al., 1999b). VEGF may, however,
regulate bone formation also through a direct
effect on osteoblasts, which express both
VEGFR-1 and VEGFR-2 (Deckers et al. ,
2000). VEGF induces the migration and
increases alkaline phosphatase activity in
cultured osteoblasts in vitro (Mayr-wohlfart
et al., 2002; Midy and Plouet, 1994).
Furthermore, VEGF appears to be required
for normal chondrocyte maturation and
regulation of osteoblastic activities in vivo
(Zelzer et al., 2002).
Indirectly, VEGFs and their receptors
may control organ morphogenesis. Recent
studies indicated that prior to their vascular
function endothelial cells and nascent vessels
can guide the early development of the liver
and pancreas (Lammert et al., 2001;
Matsumoto et al., 2001). In the absence of
endothelial cells the outgrowth of the liver
bud was inhibited (Matsumoto et al., 2001).
On the other hand, endothelial cells secrete
factors which induce embryonic endoderm to
differentiate into pancreas, suggesting that
vessels can provide inductive signals for
organ development (Lammert et al., 2001).
4. Pathologic conditions involving blood and lymphatic vessels
The pathophysiology of several diseases is
affected by insufficient or excessive
angiogenesis and/or lymphagiogenesis. For
example, the chronic inflammation in
rheumatoid arthritis is sustained due to
excessesive angiogenesis, caused by
production of angiogenic factors from
infiltrating macrophages and inflammatory
cells. On the other hand, duodenal ulcers are
devoid of vessels and stimulation of
angiogenesis might be a strategy to accelerate
their healing. Since blood and/or lympatic
vessels have a central role in a number of
pathological conditions, the ability to control
their growth could provide strategies for the
treatment of such diseases.
4.1. Tumor development and progression
Tumor cells are often undifferentiated cells
which overexpress several growth factors and
growth factor receptors and can stimulate
their own growth. Tumor cells also secrete
angiogenic factors, such as VEGF, and thus
they can induce the growth of blood vessels.
In order to grow larger than a few millimeters
in diameter the newly formed vessels are
needed to provide nutrients and oxygen for
tumor cells (Folkman, 1996). Therefore, the
tumor-induced stimulation of blood vessel
growth is considered to play a critical role in
controlling tumor growth.
Metastasis of tumor cells by direct
invasion or via blood or lymphatic vessels is
one of the leading causes of death in cancer
patients (Plate ,  2001) .  Although
hematogenous metastasis via blood vessels is
well recognised, for many tumors the most
common pathway for metastatic spread is via
lymphatic vessels. In addition, the lymphatic
spread of tumor cells to regional lymph nodes
is an indicator of tumor aggressiveness. In
general, it is thought that high interstitial
pressure inside the tumor prevents the growth
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of lymphatic vessels into the tumor cell mass
(Carmeliet and Jain, 2000). However, the
studies of the involvement of the lymphatic
vessels in tumor growth were hampered for a
long time due to absence of specific markers
of lymphatic endothelium.
Several experimental studies have
recently demonstrated an important role for
lymphatic vessels as a route for tumor
metastasis. Overexpression of the VEGFR-3
ligands, VEGF-C or VEGF-D, by tumor cells
induced lymphangiogenesis in the tumor
periphery, but also intralymphatic tumor
growth and metastasis. These studies were
done using transfected cells (Karpanen et al.,
2001; Skobe et al., 2001; Stacker et al., 2001)
or transgenic mice (Mandriota et al., 2001),
but correlation of VEGF-C expression with
increased lymphatic metastasis has also been
reported in several human cancers (Ohta et
al., 1999; Tsurusaki et al., 1999; Yonemura
et al., 1999). In addition, when highly
metastatic tumor cells were selected from a
human cancer cell line, those cell clones
which displayed high metastatic potential
expressed VEGF-C although the parental cell
line did not (He et al., 2002). These studies
suggest that VEGF-C or VEGF-D secreting
tumors can activate the growth of lymphatic
vessels which may then facilitate metastasis
of tumor cells.
Inhibition of tumor angiogenesis is
considered to be one of the most promising
therapeutic strategies to inhibit tumor growth.
Presumably anti-angiogenic therapies can act
on any tumor type, do not induce tumor cell
resistance and should not affect normal
tissues (Plate, 2001). Since VEGFs and their
receptors are major regulators of both
angiogenesis and lymphangiogenesis, they
are excellent targets for cancer therapy.
Dominant-negative VEGFR-2, neutralising
VEGF antibodies or soluble VEGFR-1 or
VEGFR-2 proteins have been successfully
used in the inhibition of tumor angiogenesis
and growth in mouse models (Goldman et al.,
1998; Kong et al., 1998; Lin et al., 1998a;
Millauer et al., 1994; Takayama et al., 2000).
On the other hand, tumor lymphagiogenesis
and metastasis were inhibited by blocking
VEGF-C or VEGF-D actions with
neutralising antibodies or soluble VEGFR-3
protein (He et al., 2002; Karpanen et al.,
2001; Stacker et al., 2001).
Another promising strategy for cancer
therapy is to target drugs specifically to
tumors. Selective expression of certain
molecules in tumor vasculature has allowed
the isolation of peptides that specifically
recognise the tumor blood vessels. When
linked to chemoterapeutic drugs these
peptides can facilitate efficient drug delivery
into the tumor and thus reduce the toxicity of
the drug to other tissues (Arap et al., 1998).
The screening of phage-displayed peptide
libraries has also allowed the isolation of
peptides which selectively home in on the
vasculature of individual organs and tissues
(Arap et al., 2002; Essler and Ruoslahti,
2002). These peptides may facilitate organ-
specific drug targeting in a variety of
pathological conditions, including cancer.
4.2. Lymphedema
Lymphedema is a disorder characterised by
insufficiency of the lymphatic system which
leads to accumulation of protein-rich fluid in
the tissues and to a disfiguring and disabling
swelling of the extremities. Ultimately, the
patients also suffer from tissue fibrosis and
adipose degeneration, from impaired wound
healing and have higher susceptibility to
infections (Witte et al., 2001). Noninherited
secondary or aquired lymphedema develops
when the lymphatic vessels are damaged for
example by surgery or radiation therapy or
obstructed by filarial infection. In contrast,
inherited primary lymphedema is usually due
to hypoplasia or aplasia of the superficial or
subcutaneous lympatic vessels.
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In some families of hereditary
lymphedema heterozygous missense
mutations were found in VEGFR-3 gene. All
the lymphedema-associated mutations
inactivated the tyrosine kinase domain and
therefore led to insufficient VEGFR-3
signaling (Irrthum et al., 2000; Karkkainen et
al., 2000). However, primary lymphedemas
are a heterogenous group of disorders which
are also sometimes associated with additional
malformations of other organs. In
lymphedema distichiasis, characterised by
congenital lymphedema, double row of
eyelashes and other complications, mutations
were reported in the FOXC2 gene. FOXC2 is
a forkhead transcription factor, which
regulates cardiovascular development and
somitogenesis in mice (Winnier et al., 1997;
Winnier et al., 1999). Most of the
lymphedema-linked FOXC2 mutations cause
premature termination in the protein and are
likely to produce haploinsufficiency (Bell et
al., 2001; Fang et al., 2000; Finegold et al.,
2001).
Genetically modified mouse mutants
have provided important tools for the studies
of molecular mechanisms involved in
lymphatic growth and development of
lymphedema (Table II). A mouse model for
human lymphedema was obtained using N-
ethyl-N-nitrosourea-induced chemical
mutagenesis. Like in human lymphedema,
heterozygous mice carrying an inactivating
missense mutation in VEGFR-3 gene had
hypoplastic dermal lymphatic vessels
(Karkkainen et al., 2001). In addition, the
mice had leaky intestinal lymphatics, which
resulted in accumulation of intraperitoneal
chylous fluid after suckling. Since the mice
carrying only one functional VEGFR-3 gene
allele appeared normal (Dumont et al., 1998)
while tyrosine kinase inactivating mutation
caused lymphedema, the phenotype was
suggested to arise due to a “dominant-
negative” effect by the kinase inactive
receptor. Despite this, gene therapy using
a d e n o v i r a l  V E G F - C  i n d u c e d
lymphangiogenesis in the lymphedema mice,
suggesting a therapeutic application for
human disease (Karkkainen et al., 2001).
We have also evidence that in
different mouse backgrounds the reduction of
the VEGFR-3 gene dosage is sufficient to
cause a lymphedema-like phenotype
(unpublished observations). The dependence
of the phenotype on the genetic background
resembles the observed variability in the
penetrance of human lymphedema, and
suggests that genes modulating either
VEGFR-3 activated or other yet
uncharacterised signaling pathways may
significantly contribute to the development of
the disease. Similar background-dependent
lymphatic phenotypes, determined by
accumulation of chylous ascites, have been
previously observed in mice deficient of
Prox-1 (Wigle and Oliver, 1999), Ang-2 (G.
Thurston, pers. comm.) or transcription factor
Sox18 (Pennisi et al., 2000a; Pennisi et al.,
2000b; Table II). In endothelial cells, Sox18
interacts with a MADS-family transcription
factor MEF2C which potentiates its
transcriptional activity (Hosking et al., 2001).
Interestingly, targeted mutagenesis of
MEF2C leads to a similar phenotype as
observed in VEGFR-3 deficient mice.
MEF2C deficient embryos die at E9.5-10 due
to defects in the remodeling of the primary
vasculature and abnormal endocardiogenesis
(Bi et al., 1999; Lin et al., 1998b). While the
endocardial defects may be caused by
significant decrease in Ang-1 and VEGF
expression in the myocardium (Bi et al. ,
1999), decreased VEGFR-3 expression may
contribute to the failure in vascular
remodeling. In line with this hypothesis,
VEGFR-3 promoter region contains a
conserved binding motif for MEF2 (Iljin et
al., 2001). In conclusion, both Sox18 and
MEF2C may participate in a common
transcriptional program involved in the
development of the lymphatic vasculature.
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Table II. Mouse mutants having a lymphatic phenotype
Gene
Mouse
model1 Lymphatic phenotype Lethality2 Reference
Prox-1 KO Defective lymphatic sprouting and
differentiation (-/-)
Accumulation of chylous ascites (+/-)
E14.5
P2-3
Wigle and Oliver,
1999
Integrin α9 KO Chylothorax (-/-) P6-12 Huang et al., 2000
Ang-2 KO Disconnected lymphatic vessels,
accumulation of chylous ascites
G. Thurston, pers.
comm.
VEGFR-3 Mut
(kinase dead)
Accumulation of chylous ascites,
hypoplasia of dermal lymphatic vessels
(+/mut)
viable Karkkainen et al.,
2001
Net
transcription
factor
Mut
(loss of the Ets
DNA-binding
domain)
Chylothorax (mut/mut) P2 Ayadi et al., 2001
Sox18
transcription
factor
Mut
(truncated
transactivation
domain)
Accumulation of chylous ascites
(mut/mut)
before
weaning
Pennisi et al., 2000b
VEGF-C TG
(K14 promoter)
Hyperplasia of dermal lymphatic
vessels
viable Jeltsch et al., 1997
(Insulin promoter) Hyperplasia of lymphatic vessels
around the islets of Langerhans
viable Madriota et al., 2001
VEGF-D TG
(K14 promoter)
Hyperplasia of dermal lymphatic
vessels
viable Veikkola et al., 2001
VEGFR-3-Ig
(VEGF-C/D
“trap”)
TG
(K14 promoter)
Lack of dermal lymphatic vessels viable Mäkinen et al., 2001a
1 KO = knock-out (gene inactivation), Mut = mutagenesis (chemically induced (VEGFR-3) / gene-targeted (Net)
/ spontaneous (Sox18)), TG = transgenic (gene overexpression)
2 E = embryonic day, P = postnatal day
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AIMS OF THE STUDY
This study was undertaken to obtain more information concerning the mechanisms of
VEGF/VEGFR interactions involved in the regulation of the growth and development of
blood and lymphatic vessels. We wanted especially to elucidate the role of VEGFR-3 and its
ligands, VEGF-C and VEGF-D, in these processes. To achieve these goals we studied:
- VEGF-B binding to the isoform-specific VEGF receptor, neuropilin-1 (I)
- the role of VEGFR-3 signaling in the development of embryonic blood and lymphatic
vessels by using a competitive inhibitor of VEGFR-3-ligand interactions (II)
- VEGFR-3 mediated signal transduction in lymphatic endothelial cells (III)
- the genetic program controlling lymphatic versus blood vascular endothelial phenotype (IV)
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MATERIALS AND METHODS
The materials and methods used are described in detail in the respective publications.
Cell line Description Source or reference Used in
293T, 293EBNA human fibroblast ATCC I
Ba/F3 mouse pre-B-lymphocytes II, III
HMVEC human dermal microvascular EC PromoCell III
HUVEC human umbilical vein EC PromoCell III
PAE porcine aortic EC Dr. L. Claesson-Welsh III
S2 Drosophila Schneider S2 cells Invitrogen I
ATCC – American Type Culture Collection
Growth factor Description Source or reference Used in
bFGF human basic FGF, FGF-2 R&D Systems III
PlGF-1 human PlGF-1 splice-isoform Dr. G. Persico III
VEGF121 human VEGF 121 splice-isoform R&D Systems I
VEGF165 human VEGF 165 splice-isoform R&D Systems III
VEGF-B167 mouse VEGF-B 167 splice-isoform Dr. B. Olofsson I
VEGF-C mature human VEGF-C (residues Thr103-
Leu215)
(Joukov et al., 1997) II, III
VEGF-C156S Cys156->Ser mutation, mature human
VEGF-C (residues Thr103-Ile225)
(Joukov et al., 1998) III
VEGF-D mature human VEGF-D (residues Phe93-
Ser201)
R&D Systems III
VEGF-E (ORFV2-
VEGF)
orf-viral VEGF homolog, NZ2 isoform Dr. L. Wise
(Wise et al., 1999)
III
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Antigen Description Source or reference Used in
Akt rabbit antiserum against Akt/protein kinase B
(aff)
New England Biolabs III
CD31/PECAM-1 mouse mAb against human CD31 Dako III, IV
rat mAb against mouse PECAM-1 Pharmingen II
CREB rabbit antiserum against cAMP response
element binding protein (aff)
New England Biolabs III
LYVE-1 rabbit antiserum against mouse LYVE-1 Dr. D.G. Jackson II
rabbit antiserum against human LYVE-1 Dr. D.G. Jackson III
MAPK
(ERK1/ERK2)
rabbit antiserum against p42/p44 MAPK (aff) New England Biolabs III
myc mouse mAb (9E10) against c-myc epitope Babco I
NRP-1 rabbit antiserum against mouse NRP-1 (aff) Dr. H. Fujisawa I
PCNA mouse mAb (PC10) against proliferating cell
nuclear antigen
Santa Cruz
Biotechnology
III, IV
podoplanin rabbit antiserum against human podoplanin
(aff)
Dr. D. Kerjaschki/
H. Kowalski
III
prox-1 rabbit antiserum agains human prox-1 Dr. Jörg Wilting IV
VEGF mAb against human VEGF R&D Systems I
VEGF-B rabbit antiserum against mouse VEGF-B (aff) Dr. B. Olofsson I
VEGF-C rabbit antiserum (882) against human VEGF-C (Joukov et al., 1996) I
VEGFR-3 mouse mAb against human VEGFR-3
9D9F9
7B8F9
2E11D11
(Jussila et al., 1998) III
II
III, IV
rat mAb against mouse VEGFR-3 Dr. H. Kubo
(Kubo et al., 2000)
II
vWF mAb against human von Willebrand Factor Dako III
Abbreviations: mAb = monoclonal antibody, aff = affinity-purified
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Methods Used in
Adenoviral infection of endothelial cells IV
Analyses of cell viability and apoptosis II, III
Annexin-V staining III
MTT assay II, III
TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) II, III
Analysis of cell migration (Boyden chamber assay) III
Biosensor analysis of receptor-ligand interaction III
Cell culture I-IV
DNA cloning and subcloning I, II, IV
ELISA (enzyme-linked immunosorbent assay) I-III
FACS (fluorescence activated cell sorting) III
Generation of transgenic mice II
Immunofluorescence III, IV
Immunohistochemistry II, IV
Immunoprecipitation I
Isolation of endothelial cells using magnetic cell sorting III, IV
Lectin perfusion staining II
Magnetic resonance imaging II
Metabolic labeling I
Microarray analysis of gene expression IV
Northern blotting II-IV
PCR I, II, IV
Preparation of mouse tissues II
Receptor stimulation and ligand binding I, III
RNA extraction II-IV
RT-PCR IV
Southern blotting II
Transfection I
Visualisation of lymphatic vessels in mice (by Dextran and Evans blue dye) II
Western blotting I-III
X-Gal staining of tissues II
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RESULTS AND DISCUSSION
1. Neuropilin-1 is a receptor for VEGF-B (I)
Neuropilin-1 (NRP-1) controls axon growth
and guidance through interactions with
Semaphorins. In addition, NRP-1 was shown
to act as a receptor for certain splice-isoforms
of VEGF and PlGF, and it was speculated to
modulate VEGF-induced angiogenesis.
Based on the high homology with VEGF and
PlGF, we asked whether VEGF-B also binds
to NRP-1.
VEGF-B is expressed as two
isoforms, VEGF-B167 and VEGF-B186, which
are generated by alternative splicing
(Olofsson et al., 1996b). VEGF-B167 has a
basic, heparin binding C-terminus, by which
the protein becomes sequestered to the cell
surface after secretion. However, in VEGF-
B186 an alternative splice acceptor site in exon
6 generates an insertion and frameshift in the
coding sequence, giving rise to a different C-
terminus and to a soluble, O-glycosylated
protein (Olofsson et al., 1996b). The common
N-terminal cystine knot growth factor domain
of VEGF-B (amino acid residues 1-115) is
responsible for binding to VEGFR-1
(Olofsson et al., 1998).
We constructed a soluble neuropilin-1
Ig-fusion protein and used it for the binding
studies with metabolically labelled growth
factors. In these expriments we found that
both splice-isoforms of VEGF-B bind to
neuropilin-1 (Makinen et al., 1999; I).
Interestingly, only the proteolytically cleaved
form of VEGF-B186 was able to bind NRP-1.
The NRP-1 binding epitopes were different
from the VEGFR-1 binding epitopes, and the
former were located in the C-termini of the
two isoforms. We also found that the binding
of VEGF-B167 to NRP-1 was mediated by the
heparin-binding domain encoded by exon 6B.
This domain is highly homologous to the
NRP-1 binding epitopes of VEGF165 and
PlGF-2. In contrast, the NRP-1 binding of
VEGF-B186 was regulated by the exposure of
a short C-terminal proline rich peptide upon
proteolytic processing, which thus constituted
a novel NRP-1 binding epitope. The
proteolytic processing site was further
mapped to Arg-127 with mass-spectrometry
and therefore the NRP-1 binding epitope
constituted minimally only 12 amino acid
residues.
NRP-1 and VEGF-B are co-expressed
for example in the myocardial cells of the
developing heart and in the smooth muscle
cells surrounding blood vessels (Aase et al.,
1999; Kitsukawa et al., 1995). In addition,
the juxtacrine relationship between NRP-1 in
endothelial cells and VEGF-B in the
surronding smooth muscle cells suggests that
the molecules are used for paracrine
communication between these cells.
Because a NRP-1 deletion mutant
lacking the intracellular domain can mediate
Sema3A-induced growth cone collapse, it
was concluded that rather than having a
signaling function of its own, NRP-1
functions as a co-receptor for other signal
transducing receptor(s) (Nakamura et al.,
1998). Indeed, it was found that NRPs form
complexes with receptors of the plexin
family, plexin-A1 and plexin-A2, which are
responsible for mediating chemorepulsion
(Rohm et al., 2000; Takahashi et al., 1999a;
Tamagnone et al., 1999). Similarly, NRPs
regulate signal transduction by VEGFRs
through formation of complexes with them
(Fuh et al., 2000; Gluzman-Poltorak et al.,
2001; Whitaker et al., 2001).
No obvious protein homology
domains have been found in the relatively
short intracellular domain of NRP-1, which
consists of 40 amino acid residues. However,
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the intracellular domain is highly conserved
between species, suggesting importance of
this part for NRP-1 function. A PDZ-domain
containing protein NIP was shown to interact
with NRP-1 intracellular domain (Cai and
Reed, 1999). NIP may link NRP-1 with other
signaling molecules or with the cytoskeleton,
suggesting that NRP-1 has also an intrinsic
signaling function.
NRP-1 appears to function also as a
cell surface adhesion molecule (Takagi et al.,
1995). Interaction with another adhesion
molecule, L1-CAM, may be involved in the
NRP-1 mediated cell adhesion activity.
However, in addition to its adhesive function,
L1-CAM modulates Semaphorin signals by
forming tripartite complexes with plexins and
NRPs (Castellani et al., 2000). Interestingly,
L1-CAM has been shown to turn Sema3A
induced repulsion of neuronal growth cones
into attraction (Castellani et al., 2000).
In summary, our studies show that
NRP-1 functions as a receptor for both splice-
isoforms of VEGF-B. Since the biological
function(s) of VEGF-B, as well as the
VEGFR-1 mediated signaling have remained
largely unknown, it has been difficult to
define the role of NRP-1 binding in the
biology of VEGF-B. However, analogous to
VEGF and Semaphorins, VEGF-B may
induce biological responses such as cell
migration in cells which express NRP-1, but
no VEGFRs. NRP-1 may also potentiate the
effects of VEGF-B in cells where VEGFR-1
is expressed. Furthermore, competitive
interactions between Semaphorins and
VEGFs may regulate the biological responses
both in endothelial cells and in neurons.
2. VEGFR-3 is required for the development and maintenance of the embryonic lymphatic
vasculature (II)
VEGFR-3 is expressed in lymphatic
endothelial cells in adult tissues and its
ligands were reported to stimulate
lymphangiogenesis (Jeltsch et al., 1997; Oh
et al., 1997). However, homozygous
disruption of VEGFR-3 led to death of mouse
embryos before the emergence of lymphatic
vessels and thus these mice did not provide
any information on the role of VEGFR-3 in
the development of lymphatic vessels
(Dumont et al., 1998). In order to address this
question, we used a soluble VEGFR-3 as a
competitive inhibitor of VEGF-C/VEGFR-3
signaling (Fig. 4).
According to our in vitro experiments,
a fusion protein consisting of the ligand
binding portion of human VEGFR-3 and
human IgG1 Fc domain (VEGFR-3-Ig)
efficiently inhibited VEGF-C/D binding to
their cell surface receptors and blocked
VEGFR-3 signaling. To test the inhibitory
effect of VEGFR-3-Ig in vivo, we generated
transgenic mice expressing the fusion protein
under the keratin-14 (K14) promoter which
directs the transgene expression to the basal
epidermal cells of the skin. The K14-driven
transgene expression is turned on after the
developmental period when lymphatic vessel
development has started and VEGFR-3
expression has been downregulated in blood
vessels. The late onset of the transgene
expression should eliminate the presumably
lethal effects of the inhibition of VEGFR-3
signaling on the blood vasculature.
Transgenic K14-VEGFR-3-Ig mice
were devoid of dermal lymphatic vessels as
evaluated by histochemistry, immunostaining
and lack of lymphatic transport of
macromolecules injected into the dermis. In
contrast, the blood vasculature remained
normal, indicating that the inhibition was
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specific for the lymphatic vessels (Mäkinen
et al., 2001a; II).
Neutralising levels of circulating
soluble VEGFR-3-Ig protein in the sera of the
transgenic mice were also associated with a
transient loss of lymphatic vessels in several
internal organs of neonatal mice. However,
after three weeks of age, partial regeneration
of the lymphatic vessels was observed,
suggesting that alternative pathways may be
involved in mediating the growth of the
lymphatic vessels. For example, the maturing
extracellular matrix may provide signals for
the survival and proliferation of lymphatic
endothelial cells, and new lymphatic vessels
may grow alongside the existing blood
vessels and receive proliferative and
chemotactic signals from the blood vessel
endothelial cells. Similar results of vessel
regeneration have been obtained using
adenoviral VEGFR-3-Ig. Adenoviral
infection of newborn mouse pups results in
the regression of lymphatic vessels, but the
vessels regenerate in a few weeks in spite of
the high serum levels of the VEGFR-3-Ig
protein (Karpanen et al., unpublished
observations). However, in adult mice
AdVEGFR-3-Ig fails to induce the regression
of normal lymphatic vessels (He et al., 2002;
Karpanen et al., 2001; Karpanen et al. ,
unpublished observations). These results
suggest the existence of a mechanism of
lymphatic vessel maturation after which the
growth and survival of the vessels may no
longer be (totally) dependent on VEGF-C.
For the blood vessels, pericyte recruitment
acts as a signal for vessel maturation, after
which the endothelial cells can survive in the
absence of VEGF (Benjamin et al., 1998).
Figure 4. Inhibition of VEGFR-3
signaling by the transgenic expression of a
soluble VEGFR-3 Immunoglobulin (Ig)-
fusion protein. Visualisation of dermal
blood and lymphatic vessels in the wild
type and transgenic mice. Inhibition of
VEGFR-3 signaling leads to a specific
inhibition of lymphangiogenesis.
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The absence of dermal lymphatic
vessels in the K14-VEGFR-3-Ig mice was
associated with fibrosis, increased fluid
accumulation in the skin and subcutaneous
tissue and swelling of the feet. The phenotype
thus resembled human lymphedema, and
supported the human studies which
demonstrated the deficient VEGFR-3
signaling as the cause of the disease (Irrthum
et al., 2000; Karkkainen et al., 2000).
Furthermore, as in some cases of
lymphedema, the size and appearance of
certain lymph nodes varied in the transgenic
mice, indicating that lymph flow and a
functional lymphatic vasculature are essential
for the formation of normal lymph nodes.
The early development of the lymphatic
vasculature was not disturbed in the
transgenic mice. However, in parallel with
significant increase in K14 promoter activity
and transgene encoded protein expression,
the dermal lymphatic vessels regressed in the
transgenic embryos via apoptosis of
lymphatic endothelial cells. In conclusion,
our results suggest that continuous VEGFR-3
signaling is required not only for the
proliferation but also for the survival of the
lymphatic endothelial cells and thus for both
the development and maintenance of the
lymphatic vasculature during embryonic
development.
3. VEGFR-3 transduces lymphatic endothelial cell growth, survival and migration signals
(III)
As the VEGF receptors are key mediators of
angiogenic responses, the signal transduction
pathways initiated in endothelial cells upon
their activation have been under extensive
study. These studies have been mainly carried
out using transfected cell lines, but lack of an
appropriate cellular background can
compromise results obtained from such
studies. In addition, little was known of the
VEGFR-3 activated signal transduction. In
order to clarify these questions, we used a
VEGFR-3 specific mutant form of VEGF-C
(Joukov et al., 1998) and primary cultures of
human dermal microvascular endothelial
cells for the studies of VEGFR-3 mediated
cellular signaling.
Figure 5. Human dermal microvascular
endothelial cells in culture. The lymphatic
endothelial cells (stained in red) grow in
distinct islands surrounded by blood
vascular endothelial cells. The nuclei of all
cells have been stained blue.
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3.1. Isolation of lymphatic endothelial cells
Based on the expression of three lymphatic
endothelial cell specific markers, VEGFR-3,
podoplanin and LYVE-1, we found that the
microvascular endothelial cell cultures
consisted of two lineages of blood vascular
and lymphatic endothelial cells (Fig. 5). The
lymphatic endothelial cells (LECs) grew in
distinct islands surrounded by blood vascular
endothelial cells (BECs). We then used
antibodies against VEGFR-3 or podoplanin
and magnetic microbeads for the separation
of BECs and LECs, and maintained the
isolated cells in culture (Mäkinen et al. ,
2001b; III). No interconversion between the
cell types was detected in the cultures. In an
independent study by Kriehuber et al. (2001)
BECs and LECs were separated from dermal
cell suspension by flow cytometry using
antibodies against podoplanin and CD34
(Kriehuber et al., 2001). In agreement with
our results their studies demonstrated that
LECs and BECs constitute stable and
specialized EC lineages.
The ability to isolate and to culture
BECs and LECs allowed us to study the
signal transduction pathways of different
VEGF receptors in these two cell lineages.
Both BECs and LECs expressed VEGFR-1
and VEGFR-2 while VEGFR-3 was mainly
detected in LECs. On the other hand, BECs
produced VEGF-C and extracellular matrix
components (III; Kriehuber et al., 2001;
unpublished observations), which were
required for the growth and survival of the
LECs. We found that VEGFR-3 activation
induced survival, migration and proliferation
of LECs, while VEGFR-2 stimulated these
processes in both cell lineages.
3.2. VEGFR-3 signal transduction
In earlier studies with transfected cells
VEGFR-3 has been reported to associate with
Grb2, Shc and Sos adaptor proteins (Fournier
et al., 1995; Pajusola et al., 1994; Wang et
al. ,  1997)  and to induce MAPK
phosphorylation (Joukov et al., 1998). Shc
promotes VEGFR-3 dependent cell
proliferation by the activation of the Ras
pathway. Other reported substrates for
VEGFR-3 include a non-receptor tyrosine
kinase Pyk2 (proline-rich kinase 2, also
called RAFTK for related adhesion focal
tyrosine kinase, CAKß for cell adhesion
kinase ß and FAK2 for focal adhesion kinase
2; (Liu et al., 1997; Wang et al., 1997). Pyk2
activates serine kinases ERK and JNK (Jun
NH2-terminal kinase) and phosphorylates the
focal adhesion molecule paxillin (Fig. 6).
Paxillin phosphorylation then leads to
recruitment of actin-anchoring proteins into
the focal adhesions and to actin
reorganisation which is associated with cell
migration. In contrast, Pyk2 induced JNK
activation stimulates cellular proliferation via
the modulation of transcriptional activation
factors such as AP1.
When we studied the basis for the
VEGFR-3 transduced survival and migratory
signals in primary cultures of endothelial
cells, we detected activation of two important
signaling molecules which have been
associated with cell proliferation and
survival; ERK1/ERK2 (p42/p44 MAPK) and
Akt.
VEGFR-3 induced MAPK activation
was mediated via PKC, not via Ras, similarly
to what has been previously shown for
VEGFR-2 (Doanes et al., 1999; Takahashi et
al., 1999b; Yoshiji et al., 1999). Such a
pathway is rather unique among receptor
tyrosine kinases since classically PKC-
dependent MAPK activation was thought to
be employed mainly by certain seven-
transmembrane, G protein-coupled receptors.
Although the activation of the p42/p44
MAPK cascade is linked in many cells to a
proliferation response, this pathway can also
lead to increased cell survival (Bonni et al.,
1999; Gupta et al., 1999).
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VEGFR-3 stimulated phosphorylation
of Akt was dependent on PI3-kinase activity.
In spite of this, we were not able to detect the
association of VEGFR-3 with the regulatory
subunit of PI3-kinase, p85. This may indicate
that PI3-kinase does not directly bind
VEGFR-3 or that the interaction between
these molecules is transient.
In addition to VEGFR-3, the LECs
also expressed VEGFR-1 and VEGFR-2.
Interestingly, VEGFR-2 activation stimulated
the proliferation, migration as well as
survival of both BECs and LECs, suggesting
that VEGF, via VEGFR-2, can regulate
signal transduction also in LECs. In addition,
even the highest concentrations of the
VEGFR-3 specific mutant form of VEGF-C
were not as effective as VEGF-C in
promoting survival or migration, suggesting
that activation of both VEGFR-2 and
VEGFR-3 may be required for the VEGF-C-
induced maximal responses in LECs. These
results suggest that VEGFR-2 may have an
important role in the regulation of signal
transduction in lymphatic endothelial cells
and possibly also in the regulation of
lymphangiogenesis in vivo.
Figure 6. Tyrosine residues (Y) in the cytoplasmic domain of VEGFR-3 and VEGFR-3 activated intracellular
signaling molecules. Dashed line: a direct interaction or activation has not been shown.
4. A genetic program controlling the lymphatic versus blood vascular endothelial cell
phenotype (IV)
4.1. Gene expression profiling of lymphatic
and blood vascular endothelial cells
Identification of differentially expressed
genes between BECs and LECs may provide
new potential vascular markers, and also give
a better understanding of the structural and
functional properties of these cells. After
establishing the isolation and culture of BECs
and LECs, we addressed the question of the
genetic program controlling the identity of
these two cell lineages using a gene profiling
approach.
For the gene expression studies, we
used Affymetrix oligonucleotide microarrays
which contain sequences from about 12.000
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known genes, i.e approximately 30% of the
total number of all predicted human
transcripts. We identified ~300 genes which
were differentially expressed between the
cultured BECs and LECs. The most striking
differences were detected in genes which
encode for proteins involved in cytoskeletal
and cell-cell or cell-matrix interactions as
well as in the expression of pro-inflammatory
cytokines and chemokines (Petrova et al.,
submitted, IV; Mäkinen et al., manuscript in
preparation). We also identified several genes
previously unknown in the context of
endothelial cell biology, which were
differentially expressed in the two cell
lineages. Several such genes have been
originally cloned from neural tissues. Our
gene expression profiling data therefore
support the view (Shima and Mailhos, 2000)
that the same molecular mechanisms which
are involved during neuronal development
may also be commonly used in the
development of the vascular system as well
as in the establishment of the BEC and LEC
identity.
4.2. Adhesion molecules in lymphatic and
blood vascular endothelial cells
Integrins are a family of membrane receptors
which are important mediators of cell
adhesion, migration and survival (Giancotti
and Ruoslahti, 1999). Integrins consist of two
polypeptides, the α and ß subunits. Their
ectodomains bind extracellular matrix
proteins while the cytoplasmic domains
interact with the cytoskeleton and with
proteins involved in signal transduction.
Integrins can also act synergistically with
growth factors and share signaling pathways
initiated by RTKs. Integrins can even
modulate the activation of RTKs in the
absence of their ligands (Miyamoto et al.,
1996; Moro et al., 1998; Sundberg and
Rubin, 1996). Recently, VEGFR-3 was
shown to interact with integrin ß1, and
stimulation of ß1 with its ligands fibronectin
and collagen induced phosphorylation of
VEGFR-3 (Wang et al., 2001). Interaction
between VEGFR-3 and integrin ß1 appeared
to be also necessary for endothelial cell
migration.
In our gene profiling studies we
observed a LEC specific expression of
integrin α9, which provides a subunit for the
receptor for osteopontin and tenascin.
Interestingly, integrin α9 has been earlier
shown to be important for the normal
development of the lymphatic system. Mice
lacking integrin α9ß1 develop respiratory
failure due to the accumulation of a milky
pleural fluid and die after birth (Huang et al.,
2000). Therefore, integrin α9ß1 seems to
regulate the development of the lymphatic
vasculature, possibly via the interaction with
VEGFR-3.
Cadherins are another family of
transmembrane adhesion molecules, which
mediate the formation of stable cell-cell
junctions via homophilic cell adhesion. We
found that both BECs and LECs expressed
VE-cadherin whereas N-cadherin was
expressed exclusively in the BECs. VE-
cadherin is an important regulator of
endothelial cell survival (Carmeliet et al.,
1999a). It forms complexes with VEGFR-2
and PI-3 kinase and transmits the VEGF-
induced Akt activation (Carmeliet et al.,
1999a). Also, association of VEGFR-3 and
VE-cadherin was observed in these studies
(Carmeliet et al., 1999a). On the other hand,
N-cadherin has an important role in
mediating endothelial cell-SMC interactions
(Gerhardt et al., 2000). Our finding of the
BEC-specific expression of N-cadherin is in
line with the in vivo situation; blood but not
lymphatic capillaries are covered by
SMCs/pericytes, whose proliferation and
migration alongside the blood capillaries is
essential for the maturation of the vessels
during angiogenic stimulation.
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4.3. Prox-1 as a fate determining factor for
lymphatic endothelial cells
Homeodomain transcription factors are
important regulators of cellular fates and
development. Gene targeting studies have
demonstrated that Prox-1 homeobox
transcription factor has a crucial role in the
development of the lymphatic vasculature
(Wigle and Oliver, 1999). Therefore we
wanted to study the role of Prox-1 in the
regulation of BEC and LEC phenotypes.
Prox-1 was found to be expressed
specifically in the cultured LECs. However,
when introduced into the BECs using
adenoviral gene transfer, Prox-1 induced the
expression of certain lymphatic specific
genes,  including VEGFR-3 (IV).
Interestingly, Prox-1 overexpression also
resulted in the suppression of approximately
40% of the genes characteristic for the BECs.
These results suggest the role of Prox-1 as
one of the fate determining factors for the
LECs. Prox-1 was also capable of inducing
the expression of genes associated with S-
phase progression, which indicates that Prox-
1 may have a function in the regulation of
cell proliferation.
These results may help to explain the
phenotype observed in the Prox-1 null mice.
Targeted disruption of Prox-1 results in the
arrest of lymphatic vessel development,
whereas development of blood vessels is not
affected (Wigle and Oliver, 1999). The first
lymphatic sprouts normally bud from the
anterior cardinal vein at E10.5, but this
budding is arrested in Prox-1-/- embryos at
E11.5. Our results suggest that the default
endothelial cell differentiation state in the
absence of Prox-1 corresponds to the blood
endothelial phenotype and that Prox-1 is
required for the establishment of lymphatic
endothelial cell identity. Similar conclusions
were drawn from a recent study in which the
phenotype of Prox-1-/- embryos was analysed
in more detail (Wigle et al., 2002). Wigle et
al. showed that in contrast to the wild type
embryos, in Prox-1-/- embryos the endothelial
cells that bud off from the cardinal vein at
E11.5-E12 did not express lymphatic
endothelial cell markers VEGFR-3, LYVE-1
or SLC chemokine. Instead, the mutant cells
expressed blood vascular markers laminin
and CD34, suggesting that these cells were
not committed to the lymphatic endothelial
cell lineage in the absence of Prox-1 (Wigle
et al., 2002).
Gene targeting also revealed that Prox-
1 haploinsufficiency was associated with
accumulation of lymphatic chylous fluid and
neonatal death, suggesting that the level of
Prox-1 is critical for proper lymphatic
development (Wigle and Oliver, 1999). We
found that Prox-1 upregulates the expression
of genes associated with a proliferative
phenotype, suggesting that after the
differentiation of lymphatic endothelial cells,
Prox-1 may be also essential for the
maintenance of their proliferation during the
development.
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CONCLUDING REMARKS
Lymphatic vessels are essential for the
maintenance of normal fluid balance and
immune surveillance but they also provide a
pathway for metastasis in many types of
cancers. VEGFR-3 was identified as a
receptor expressed in the lymphatic
endothelium and its ligands, VEGF-C and
VEGF-D were reported to induce
lymphangiogenesis.
The work presented  here
demonstrated that VEGFR-3 mediates signals
for the survival, migration and proliferation
of lymphatic endothelial cells, and these
signals are essential for the normal
development of lymphatic vessels during
embryonic development. Inhibition of
VEGFR-3 signaling by using a soluble
VEGFR-3 protein resulted in a specific and
complete inhibition of lymphangiogenesis in
a mouse model. Also in tumor models the
soluble VEGFR-3 has been shown to
specifically inhibit VEGF-C-induced
lymphangiogenesis and tumor spread via
lymphatic vessels (Karpanen et al., 2001, He
et al., 2002). In cancers which show high
lymphogenous metastasis, lymphatic
eradication by inhibiting VEGFR-3 signaling
may thus provide a novel strategy to inhibit
metastasis.
Until now, only few cell lines of
lymphatic endothelial cells have been
available for molecular biological studies,
and these cells were mainly derived from
lymphatic tumours. We showed the isolation
and maintenance of primary cultures of
dermal blood vascular and lymphatic
endothelial cells (BECs and LECs,
respectively), which allows now further
characterisation of the molecular properties
of these cells. Using gene expression
profiling, we identified genes which
distinguish these two cell lineages, and
showed that the homeobox transcription
factor Prox-1 is involved in establishing the
molecular identity of LECs. Molecular
discrimination of the vessels is essential in
studies of diseases involving the blood and/or
lymphatic vessels and in the targeted
treatment of such diseases. Thus the BEC and
LEC specific molecules may provide new
targets for the treatment of these diseases.
In the future, the next challenges in
lymphatic research include the identification
of new molecular regulators of
lymphangiogenesis. The ability to isolate and
to culture LECs facilitate the cloning of novel
LEC specific genes the characterisation of
which should give us a better understanding
of the mechanisms of lymphangiogenesis.
The functional analysis of the new
lymphangiogenic regulators may also give us
novel insights into the pathogenesis of
diseases of the lymphatic system.
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